Literature DB >> 11284713

Genomic organization and characterization of splice variants of the human histamine H3 receptor.

F Cogé1, S P Guénin, V Audinot, A Renouard-Try, P Beauverger, C Macia, C Ouvry, N Nagel, H Rique, J A Boutin, J P Galizzi.   

Abstract

In the present paper we report the genomic organization of the human histamine H3-receptor gene, which consists of four exons spanning 5.5 kb on chromosome 20. Using PCR, six alternative splice variants of the H3 receptor were cloned from human thalamus. These variants were found to be coexpressed in human brain, but their relative distribution varied in a region-specific manner. These isoforms displayed either a deletion in the putative second transmembrane domain (TM), H3(DeltaTM2, 431aa) or a variable deletion in the third intracellular loop (i3), H3(Deltai3, 415aa), H3(Deltai3, 365aa), H3(Deltai3, 329aa) and H3(DeltaTM5+Deltai3, 326aa). In order to determine the biological role of the H3 receptor variants compared with the 'original' H3(445aa) receptor, three isoforms, namely H3(445aa), H3(DeltaTM2, 431aa) and H3(Deltai3, 365aa), were expressed in CHO cells and their pharmacological properties were investigated. Binding studies showed that H3(DeltaTM2, 431aa) transiently expressed in CHO cells was unable to bind [125I]iodoproxyfan, whereas both the H3(445aa) and H3(Deltai3, 365aa) receptors displayed a high affinity for [125I]iodoproxyfan [K(d)=28+/-5 pM (n=4) and 8+/-1 pM (n=5) respectively]. In addition, H3(Deltai3, 365aa) possessed the same pharmacological profile as the H3(445aa) receptor. However, in CHO cells expressing H3(Deltai3, 365aa), H3 agonists did not inhibit forskolin-induced cAMP production, stimulate [35S]guanosine 5'-[gamma-thio]triphosphate ([35S]GTP[S]) binding or stimulate intracellular Ca(2+) mobilization. Therefore the 80-amino-acid sequence located at the C-terminal portion of i3 plays an essential role in H3 agonist-mediated signal transduction. The existence of multiple H3 isoforms with different signal transduction capabilities suggests that H3-mediated biological functions might be tightly regulated through alternative splicing mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11284713      PMCID: PMC1221737          DOI: 10.1042/0264-6021:3550279

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  19 in total

1.  Preactivation permits subsequent stimulation of phospholipase C by G(i)-coupled receptors.

Authors:  J S Chan; J W Lee; M K Ho; Y H Wong
Journal:  Mol Pharmacol       Date:  2000-04       Impact factor: 4.436

2.  Basic local alignment search tool.

Authors:  S F Altschul; W Gish; W Miller; E W Myers; D J Lipman
Journal:  J Mol Biol       Date:  1990-10-05       Impact factor: 5.469

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Identification of two H3-histamine receptor subtypes.

Authors:  R E West; A Zweig; N Y Shih; M I Siegel; R W Egan; M A Clark
Journal:  Mol Pharmacol       Date:  1990-11       Impact factor: 4.436

5.  Alternative splicing directs the expression of two D2 dopamine receptor isoforms.

Authors:  B Giros; P Sokoloff; M P Martres; J F Riou; L J Emorine; J C Schwartz
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

6.  The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins.

Authors:  S E Senogles
Journal:  J Biol Chem       Date:  1994-09-16       Impact factor: 5.157

7.  Histamine homologues discriminating between two functional H3 receptor assays. Evidence for H3 receptor heterogeneity?.

Authors:  R Leurs; M Kathmann; R C Vollinga; W M Menge; E Schlicker; H Timmerman
Journal:  J Pharmacol Exp Ther       Date:  1996-03       Impact factor: 4.030

8.  Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.

Authors:  T W Lovenberg; J Pyati; H Chang; S J Wilson; M G Erlander
Journal:  J Pharmacol Exp Ther       Date:  2000-06       Impact factor: 4.030

9.  Preferential coupling between dopamine D2 receptors and G-proteins.

Authors:  J P Montmayeur; J Guiramand; E Borrelli
Journal:  Mol Endocrinol       Date:  1993-02

10.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor.

Authors:  J M Arrang; M Garbarg; J C Schwartz
Journal:  Nature       Date:  1983-04-28       Impact factor: 49.962

View more
  19 in total

1.  Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.

Authors:  Florence Gbahou; Ludwig Vincent; Marie Humbert-Claude; Joel Tardivel-Lacombe; Claude Chabret; Jean-Michel Arrang
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

Review 2.  Molecular and biochemical pharmacology of the histamine H4 receptor.

Authors:  Rob Leurs; Paul L Chazot; Fiona C Shenton; Herman D Lim; Iwan J P de Esch
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 3.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

Authors:  T A Esbenshade; K E Browman; R S Bitner; M Strakhova; M D Cowart; J D Brioni
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Immunohistochemical localization of histamine H3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinociceptive targets.

Authors:  Keri E Cannon; Paul L Chazot; Victoria Hann; Fiona Shenton; Lindsay B Hough; Frank L Rice
Journal:  Pain       Date:  2006-11-28       Impact factor: 6.961

6.  Functional histamine H3 and adenosine A2A receptor heteromers in recombinant cells and rat striatum.

Authors:  Ricardo Márquez-Gómez; Meridith T Robins; Citlaly Gutiérrez-Rodelo; Juan-Manuel Arias; Jesús-Alberto Olivares-Reyes; Richard M van Rijn; José-Antonio Arias-Montaño
Journal:  Pharmacol Res       Date:  2017-12-05       Impact factor: 7.658

7.  A single-point mutation (Ala280Val) in the third intracellular loop alters the signalling properties of the human histamine H₃ receptor stably expressed in CHO-K1 cells.

Authors:  Cecilia Flores-Clemente; Angélica Osorio-Espinoza; Juan Escamilla-Sánchez; Rob Leurs; Juan-Manuel Arias; José-Antonio Arias-Montaño
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

8.  Signal transduction by histamine in the cerebellum and its modulation by N-methyltransferase.

Authors:  Motohiko Takemura; Nobue Kitanaka; Junichi Kitanaka
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

Review 9.  New molecular targets for treatment of peptic ulcer disease.

Authors:  Frank Lehmann; Pius Hildebrand; Christoph Beglinger
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases.

Authors:  C Y Jin; O Anichtchik; P Panula
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.